Although early in development, our current proof-of-concept experiments, we evaluated the efficacy ofMECP2 expressing lentiviral vector transduced human CD34+ HSPC transplanted in an immunodeficient mouse model of Rett syndrome. This evidence concerns the gene CD34 and atypical Rett syndrome.